Company / Return on Equity (ROE)
SUTRO BIOPHARMA, INC. Return on Equity (ROE) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-510.0%
FY2025
5-year range
-510.0% / -35.9%
FY2021-FY2025
Trend
-540.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SUTRO BIOPHARMA, INC. reports negative total equity of -510.0% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-510.0% in FY2025 with a 5-year CAGR of -483.1%.
Declined from -41.8% to -510.0% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -474.1pp
- 5-Year Change
- -483.1pp
- 10-Year Change
- -
Key checks
Key Insights
- SUTRO BIOPHARMA, INC.'s return on equity (roe) has declined for 3 consecutive years.
- In FY2025, return on equity (roe) decreased 540.2% year-over-year.
- Peak return on equity (roe) was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -3.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -510.0% | -540.2% |
| FY2024 | -79.7% | -90.6% |
| FY2023 | -41.8% | -16.4% |
| FY2022 | -35.9% | +37.0% |
| FY2021 | -57.0% | -112.3% |
| FY2020 | -26.9% | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026